Young doctor working

2014 Financial results

Pascal Soriot, Chief Executive Officer, commenting on the results, said:

"I’m pleased to report our third consecutive quarter of revenue growth, driven by a strong contribution from our growth platforms. Brilinta, respiratory and diabetes, our three core franchises, increased sales by 38 percent in the quarter, supported by continued selective allocation of sales and marketing resources. In addition, we have chosen to invest in our rapidly developing pipeline that will continue to create value for AstraZeneca in 2015 and beyond.

“We have made important progress towards achieving scientific leadership across all core therapeutic areas, including a positive opinion by the CHMP for Lynparza (olaparib), the FDA approval for Movantik, the launch of the Bydureon Pen in the US, and the progress of our immuno-oncology pipeline presented at ESMO. This momentum is further evidenced by the successful completion of our strategic business combination with Almirall, strengthening our respiratory franchise.

“This enhanced execution of our strategy and our sustained performance gives us confidence to increase our revenue and Core earnings guidance for the year. I’m particularly proud of our teams who continue to demonstrate their focus and belief in our strategy, which is rapidly transforming our company.”

Teleconference replay

A recording of the analyst presentation and Q&A session will be available until 17:00 GMT Wednesday 19th November, on the following numbers:

LocationNumberConference ID
UK local 0800 953 1533 29619150#
US (freephone) 1 866 247 4222 29619150#
International +44 (0) 1452 55 00 00 29619150#


Keeping investors in touch

Download our iPad app now from the app store

The AstraZeneca Investor Relations iPad app provides instant access to our latest news, webcasts and presentations, events and leadership videos.

Download and install from the iTunes store